

Patrick J Stiff

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1564660/publications.pdf>

Version: 2024-02-01

124
papers

4,311
citations

201674

27
h-index

110387

64
g-index

126
all docs

126
docs citations

126
times ranked

5870
citing authors

#	ARTICLE	IF	CITATIONS
1	Palifermin for Oral Mucositis after Intensive Therapy for Hematologic Cancers. <i>New England Journal of Medicine</i> , 2004, 351, 2590-2598.	27.0	791
2	Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet</i> , 2015, 385, 1853-1862.	13.7	633
3	Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 4284-4292.	1.6	431
4	Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment. <i>Journal of Clinical Investigation</i> , 2014, 124, 3121-3128.	8.2	224
5	Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. <i>Blood</i> , 2021, 137, 751-762.	1.4	183
6	Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. <i>Blood</i> , 2018, 132, 2639-2642.	1.4	172
7	Palifermin Reduces Patient-Reported Mouth and Throat Soreness and Improves Patient Functioning in the Hematopoietic Stem-Cell Transplantation Setting. <i>Journal of Clinical Oncology</i> , 2006, 24, 5186-5193.	1.6	130
8	Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide. <i>Journal of Clinical Oncology</i> , 2019, 37, 367-374.	1.6	110
9	Treatment with Plerixafor in non-Hodgkin's Lymphoma and Multiple Myeloma Patients to Increase the Number of Peripheral Blood Stem Cells When Given a Mobilizing Regimen of G-CSF: Implications for the Heavily Pretreated Patient. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 249-256.	2.0	104
10	Salvage Second Hematopoietic Cell Transplantation in Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 760-766.	2.0	98
11	Regulation of Ovarian Cancer Prognosis by Immune Cells in the Tumor Microenvironment. <i>Cancers</i> , 2018, 10, 302.	3.7	94
12	Management strategies for the hard-to-mobilize patient. <i>Bone Marrow Transplantation</i> , 1999, 23, S29-S33.	2.4	81
13	Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand-1 (PD-L1) in ovarian cancer. <i>Journal of Ovarian Research</i> , 2018, 11, 43.	3.0	60
14	Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis. <i>British Journal of Haematology</i> , 2018, 182, 916-920.	2.5	59
15	Fate of Patients with Newly Diagnosed Acute Myeloid Leukemia Who Fail Primary Induction Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 559-564.	2.0	58
16	The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory hodgkin disease: A southwest oncology group phase II trial. <i>Biology of Blood and Marrow Transplantation</i> , 2003, 9, 529-539.	2.0	55
17	Evaluation of the International Prognostic Score (IPS) and a Simpler Prognostic Score (IPS) for advanced Hodgkin lymphoma in the modern era. <i>British Journal of Haematology</i> , 2015, 171, 530-538.	2.5	54
18	Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study. <i>Blood</i> , 2021, 138, 1429-1440.	1.4	54

#	ARTICLE	IF	CITATIONS
19	A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial of Presatovir for the Treatment of Respiratory Syncytial Virus Upper Respiratory Tract Infection in Hematopoietic-Cell Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2020, 71, 2777-2786.	5.8	53
20	Randomized controlled trial of individualized treatment summary and survivorship care plans for hematopoietic cell transplantation survivors. <i>Haematologica</i> , 2019, 104, 1084-1092.	3.5	46
21	A Randomized, Placebo-controlled Trial of Fidaxomicin for Prophylaxis of Clostridium difficile-associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2019, 68, 196-203.	5.8	41
22	Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 311-325.	4.2	40
23	Impact of Pretransplantation 18F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1605-1611.	2.0	39
24	Safety Analysis of Brentuximab Vedotin from the Phase III AETHERA Trial in Hodgkin Lymphoma in the Post-Transplant Consolidation Setting. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2354-2359.	2.0	33
25	Cohort-Controlled Comparison of Umbilical Cord Blood Transplantation Using Carlecortemcel-L, a Single Progenitor-Enriched Cord Blood, to Double Cord Blood Unit Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1463-1470.	2.0	31
26	Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1391-1396.	2.0	30
27	Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2016, 175, 860-867.	2.5	30
28	Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1. <i>Blood</i> , 2016, 128, LBA-6-LBA-6.	1.4	30
29	Outcomes of MYC-associated lymphomas after CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704. <i>British Journal of Haematology</i> , 2016, 174, 686-691.	2.5	27
30	The Role of Salvage Second Autologous Hematopoietic Cell Transplantation in Relapsed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e98-e107.	2.0	25
31	Final analysis of a phase IB/randomized phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): A University of Chicago phase II consortium study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4012-4012.	1.6	25
32	Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. <i>Haematologica</i> , 2020, 105, 1329-1338.	3.5	23
33	Immune Checkpoint Blockade in Gynecologic Cancers: State of Affairs. <i>Cancers</i> , 2020, 12, 3301.	3.7	22
34	Neurologic aspects of plasma cell disorders. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2014, 120, 1083-1099.	1.8	21
35	Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse. <i>Blood</i> , 2015, 126, 3172-3172.	1.4	20
36	A Randomized Phase III Trial of ABVD Vs. Stanford V +/- Radiation Therapy In Locally Extensive and Advanced Stage Hodgkin's Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496). <i>Blood</i> , 2010, 116, 415-415.	1.4	18

#	ARTICLE	IF	CITATIONS
37	Clinical and Ultrasonic Evaluation of Spleen Size during Peripheral Blood Progenitor Cell Mobilization by Filgrastim: Results of an Open-Label Trial in Normal Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 827-834.	2.0	17
38	Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703). <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 700-707.	2.0	16
39	Randomized Phase II trial of two high-dose chemotherapy regimens with stem cell transplantation for the treatment of advanced ovarian cancer in first remission or chemosensitive relapse: a Southwest Oncology Group study. <i>Gynecologic Oncology</i> , 2004, 94, 98-106.	1.4	15
40	A phase IB/randomized phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): Interim analysis of a University of Chicago phase II consortium study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4022-4022.	1.6	15
41	Updated Results from a Phase II Study of Galiximab (Anti-CD80) in Combination with Rituximab for Relapsed or Refractory, Follicular NHL.. <i>Blood</i> , 2005, 106, 2435-2435.	1.4	14
42	Necroptosis in spontaneously-mutated hematopoietic cells induces autoimmune bone marrow failure in mice. <i>Haematologica</i> , 2017, 102, 295-307.	3.5	13
43	2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma. <i>Blood</i> , 2018, 132, 2967-2967.	1.4	13
44	A Prospective Randomized Double Blind Phase 3 Clinical Trial of Anti- T Lymphocyte Globulin (ATLG) to Assess Impact on Chronic Graft-Versus-Host Disease (cGVHD) Free Survival in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT). <i>Blood</i> , 2016, 128, 505-505.	1.4	12
45	Low mean post-transplantation tacrolimus levels in weeks 2â€“3 correlate with acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation from related and unrelated donors. <i>Bone Marrow Transplantation</i> , 2019, 54, 155-158.	2.4	11
46	A phase II trial of interleukin-2 in myelodysplastic syndromes. <i>British Journal of Haematology</i> , 1998, 101, 205-207.	2.5	10
47	High-Dose Chemotherapy with Blood or Bone Marrow Transplants for Rhabdomyosarcoma. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 525-532.	2.0	10
48	Long-Term Safety Outcomes in Patients with Hematological Malignancies Undergoing Autologous Hematopoietic Stem Cell Transplantation Treated with Palifermin to Prevent Oral Mucositis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 164-169.	2.0	10
49	Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2021, 39, JCO.20.01739.	1.6	10
50	The Aethera Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following Autologous Stem Cell Transplant for Hodgkin Lymphoma. <i>Blood</i> , 2014, 124, 673-673.	1.4	10
51	Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis. <i>Leukemia and Lymphoma</i> , 2019, 60, 1934-1941.	1.3	9
52	A Phase 2, Double-Blind, Placebo-Controlled Trial of Rituximab + Galiximab Vs Rituximab + Placebo In Advanced Follicular Non-Hodgkin's Lymphoma (NHL). <i>Blood</i> , 2010, 116, 428-428.	1.4	9
53	A Phase 1 Study of ACTR087 in Combination with Rituximab, in Subjects with Relapsed or Refractory CD20-Positive B-Cell Lymphoma. <i>Blood</i> , 2019, 134, 244-244.	1.4	8
54	Randomized Phase III Trial Comparing ABVD + Radiotherapy and the Stanford V Regimen In Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the US Intergroup Trial E2496. <i>Blood</i> , 2010, 116, 416-416.	1.4	8

#	ARTICLE	IF	CITATIONS
55	Nicord Single Unit Expanded Umbilical Cord Blood Transplantation: Final Results of a Multicenter Phase I/II Trial. <i>Blood</i> , 2017, 130, 847-847.	1.4	8
56	Dendritic cell immunotherapy in ovarian cancer. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 43-53.	2.4	7
57	What is the role of autologous transplant for lymphoma in the current era?. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 74-81.	2.5	7
58	Understanding dendritic cell immunotherapy in ovarian cancer. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 643-652.	2.4	6
59	Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 911.e1-911.e7.	1.2	6
60	Clinical Experience in the Randomized Phase 3 Sierra Trial: Anti-CD45 Iodine (131I) Apamistamab [lomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Patients with Active, Relapsed/Refractory AML Not Responding to Targeted Therapies. <i>Blood</i> , 2021, 138, 1791-1791.	1.4	6
61	Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein-Barr Virus-Driven Post Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE). <i>Blood</i> , 2021, 138, 301-301.	1.4	6
62	Donor Cell Myeloid Sarcoma. <i>Case Reports in Hematology</i> , 2014, 2014, 1-4.	0.4	5
63	A 54-Year-Old Woman with Donor Cell Origin of Multiple Myeloma after Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of CML. <i>Case Reports in Hematology</i> , 2016, 2016, 1-3.	0.4	5
64	Busulfan, melphalan, and bortezomib compared to melphalan as a high dose regimen for autologous hematopoietic stem cell transplantation in multiple myeloma: long term follow up of a novel high dose regimen. <i>Leukemia and Lymphoma</i> , 2020, 61, 3484-3492.	1.3	5
65	Lymphoid and myeloid immune cell reconstitution after nicotinamide-expanded cord blood transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2826-2833.	2.4	5
66	Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2021, 195, 757-763.	2.5	5
67	A Single-Arm, Open-Label Phase 1 Study of Itacitinib (ITA) with Calcineurin Inhibitor (CNI)-Based Interventions for Prophylaxis of Graft-Versus-Host Disease (GVHD; GRAVITAS-119). <i>Blood</i> , 2020, 136, 50-51.	1.4	5
68	The Role Of Body Mass Index In Survival Outcome For Lymphoma Patients: US Intergroup Experience. <i>Blood</i> , 2013, 122, 3060-3060.	1.4	5
69	Serum Biomarkers Predict Outcomes in Advanced Hodgkin Lymphoma Independent of International Prognostic Score (IPS) and Treatment: Correlative Analysis from a Large North American Cooperative Group Trial. <i>Blood</i> , 2016, 128, 2992-2992.	1.4	5
70	Managing hematopoietic stem-cell transplant resources: the case for outpatient transplantation. <i>Leukemia and Lymphoma</i> , 2009, 50, 6-7.	1.3	4
71	Successful Umbilical Cord Blood Transplants in Adults Who Received a Nucleated Cell Dose $\approx 1 \times 10^7$ Cells/kg Processed by a Post-Thaw Non-Wash Procedure.. <i>Blood</i> , 2005, 106, 2049-2049.	1.4	4
72	Utility of the Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT) in hematopoietic stem cell transplantation (HSCT).. <i>Journal of Clinical Oncology</i> , 2017, 35, 10046-10046.	1.6	4

#	ARTICLE	IF	CITATIONS
73	Azacitadine and Low-Dose Gemtuzumab Ozogamicin for the Treatment of Poor-Risk Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), Including Relapsed, Refractory Disease.. Blood, 2009, 114, 1034-1034.	1.4	4
74	Motixafortide (BL-8040) and G-CSF Versus Placebo and G-CSF to Mobilize Hematopoietic Stem Cells for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: The Genesis Trial. Blood, 2021, 138, 475-475.	1.4	4
75	Ovarian Cancer: Therapeutic Strategies to Overcome Immune Suppression. Advances in Experimental Medicine and Biology, 2021, 1330, 33-54.	1.6	3
76	AMD3100 Combined with Standard Doses of G-Csf Leads to Rapid, Consistent Mobilization of Hematopoietic Progenitor Cells in Patients with Non-Hodgkinâ€™s Lymphoma (NHL) and Multiple Myeloma.. Blood, 2004, 104, 2847-2847.	1.4	3
77	Azacitidine Plus Gemtuzumab Ozogamicin (GO): A Novel Combination in the Treatment of Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS) in the Elderly.. Blood, 2006, 108, 1981-1981.	1.4	3
78	Molecular Inhibition of mTOR with Temsirolimus (TORISELâ„¢, CCI-779) Is a Promising Strategy in Relapsed NHL: The University of Chicago Phase II Consortium.. Blood, 2006, 108, 2483-2483.	1.4	3
79	Evaluation Of a Novel 3 Factor Prognostic Score (PS-3) For Patients With Advanced Hodgkin Lymphoma (HL) Treated On US Intergroup E2496. Blood, 2013, 122, 4277-4277.	1.4	3
80	Early Post-Transplantation Tacrolimus Levels Correlate with Acute Graft-Versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplantation from Related and Unrelated Donors. Blood, 2016, 128, 3429-3429.	1.4	3
81	CLR 131 (Iopofosine I-131) Treatment in Triple Class Refractory and Beyond Multiple Myeloma Patients: Preliminary Efficacy and Safety Results from the Phase 2 Clover-1 Trial. Blood, 2021, 138, 1652-1652.	1.4	3
82	Identification of a human erythroid progenitor cell population which expresses the CD34 antigen and binds the plant lectin Ulex europaeus I. , 1996, 23, 54-58.		2
83	Long-Term Survival Is Comparable between Palifermin-Treated and Placebo-Treated Patients (Pts) with Hematologic Malignancies (HM) Undergoing High-Dose Chemotherapy and Total Body Irradiation Followed by Autologous Hematopoietic Stem Cell Transplantation (HSCT).. Blood, 2005, 106, 2925-2925.	1.4	2
84	Incidence and Risk Factors for Developing Limbic Encephalitis in Allogeneic Stem Cell Transplantation.. Blood, 2006, 108, 2919-2919.	1.4	2
85	Plerixafor (Mozobi Â®) Plus G-CSF Is More Effective Than Placebo Plus G-CSF in Mobilizing CD34+ Hematopoietic Stem Cells in Patients with Multiple Myeloma Who Have Low (<20 cells/Î¼l) Peripheral Blood CD34+ Cell Count.. Blood, 2009, 114, 3230-3230.	1.4	2
86	Busulfan / Melphalan / Bortezomib (Bu-Mel-Vel) Vs. High Dose Melphalan As Conditioning Regimen For Autologous Hematopoietic Cell Transplantation In Multiple Myeloma (MM). Blood, 2013, 122, 3357-3357.	1.4	2
87	Allogeneic hematopoietic stem cell transplantation for mantle cell lymphoma in a heavily pretreated patient population.. Journal of Clinical Oncology, 2017, 35, 7558-7558.	1.6	2
88	High Dose Intravenous Busulfan and Melphalan Followed By Bortezomib (BuMelVel) As Conditioning With Autologous Stem Cell Transplantation (ASCT) For Patients With Multiple Myeloma (MM). Blood, 2013, 122, 3376-3376.	1.4	2
89	Multivariate analysis of PFS from the AETHERA trial: A phase III study of brentuximab vedotin consolidation after autologous stem cell transplant for HL.. Journal of Clinical Oncology, 2015, 33, 8519-8519.	1.6	2
90	Palifermin For Prevention Of Oral Mucositis Has No Negative Effect On Long-Term Outcome In Patients With Hematological Malignancies Undergoing HSCT - Long-Term Follow-Up To 15 Years. Blood, 2013, 122, 4631-4631.	1.4	1

#	ARTICLE	IF	CITATIONS
91	Myeloablative Conditioning With Intravenous Busulfan and Pentostatin (Bu/Pent) Vs. Total Body Irradiation and Cyclophosphamide (TBI/Cy) For Elderly Patients With Acute Myeloid Leukemia Or Myelodysplasia. <i>Blood</i> , 2013, 122, 5450-5450.	1.4	1
92	Transplant Strategies For The Initial Management Of Mantle Cell Lymphoma: A Single Institution Analysis. <i>Blood</i> , 2013, 122, 5533-5533.	1.4	1
93	SWOG S0410/BMT CTN 0703: A Phase II Trial of Tandem Autologous Stem Cell Transplantation (AHCT) for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma (HL) (ClinicalTrials.gov) Tj ETQq1 1 0.7843144gBT /Overlock 1	1.4	1
94	Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2016, 128, 4485-4485.	1.4	1
95	Single institution experience of brentuximab vedotin (SGN-35) impact on allogeneic transplant in patients with relapsed/refractory CD 30 positive lymphoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, e19511-e19511.	1.6	1
96	Final Report on Tandem Autologous Stem Cell Transplantation for Patients with Primary Progressive or Poor Risk Recurrent Hodgkin Lymphoma - A Two Institution Study.. <i>Blood</i> , 2005, 106, 2071-2071.	1.4	1
97	Long Term Follow-up of Allogeneic Transplantation Using BEAM Chemotherapy for Patients with Hodgkin's Lymphoma Who Relapse After Autologous Transplantation: Importance of Minimal Residual Disease At Transplant.. <i>Blood</i> , 2012, 120, 3131-3131.	1.4	1
98	Cardiac Complications Following Allogeneic Bone Marrow Transplantation: Evaluation of Risk Factors, Outcomes and Enhanced Screening for At Risk Populations.. <i>Blood</i> , 2012, 120, 3070-3070.	1.4	1
99	MYC Protein Expression, but Not High Grade Morphology, Is Associated with Poor Outcome in Non-Burkitt Diffuse Aggressive B-Cell Lymphomas: A SWOG S9704 Correlative Study. <i>Blood</i> , 2012, 120, 543-543.	1.4	1
100	Ironclad: A randomized phase III study of ibrutinib (Ibr) or no consolidation following autologous hematopoietic stem cell transplantation (AutoHCT) for relapsed/refractory activated-B-cell (ABC) subtype diffuse large B-cell lymphoma (DLBCL).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS7566-TPS7566.	1.6	1
101	Allografts for Follicular Non-Hodgkin Lymphoma: Why Never Is No Longer an Acceptable Answer. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1346-1347.	2.0	0
102	Expanding the Toolbox of Adoptive Cell Immunotherapy. <i>Journal of Clinical Oncology</i> , 2021, 39, 1479-1482.	1.6	0
103	A Prospective Cohort Study Comparing Long-Term Outcomes with and without Palifermin in Patients Receiving Hematopoietic Cell Transplantation for Hematologic Malignancies. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 837.e1-837.e10.	1.2	0
104	Allogeneic Stem Cell Transplantation (SCT) Using Rabbit-ATG (Thymoglobulin®) and 2-Gy Total Body Irradiation (TBI): Reliable Early Engraftment with Minimal Acute Graft Vs. Host Disease (AGVHD).. <i>Blood</i> , 2004, 104, 2312-2312.	1.4	0
105	Refractory Thrombocytopenia Due to Allo-Immune Anti-CD36 Complicating Unrelated Donor Bone Marrow Transplant in a CD36-Negative Recipient.. <i>Blood</i> , 2007, 110, 4951-4951.	1.4	0
106	Highlighting TH-1 Rather Than TH-17 Cytokine Network in Acute Cutaneous Gvhd. <i>Blood</i> , 2008, 112, 4372-4372.	1.4	0
107	Standard Gvhd Prophylaxis Augmented with TNF-Inhibition in Alternative Donor HCT: Lower TNFR1 Levels Correlate with Better Outcomes.. <i>Blood</i> , 2009, 114, 43-43.	1.4	0
108	Effectiveness of Reduced Toxicity Conditioning Regimen with Intravenous Busulfan Plus Pentostatin (BUPENT) in Patients Older Than 50 Years with Advanced Hematologic Malignancies.. <i>Blood</i> , 2009, 114, 3331-3331.	1.4	0

#	ARTICLE	IF	CITATIONS
109	C-Myc Is Required for Acute but Not for Chronic Hematopoietic Malignances in Pten-Null Mice.. Blood, 2009, 114, 1632-1632.	1.4	0
110	Cytogenetics Abnormalities Predict the Outcome of Allogeneic Transplantation In AML: A CIBMTR Study. Blood, 2010, 116, 680-680.	1.4	0
111	A study of denileukin diftitox to treat refractory ovarian cancer.. Journal of Clinical Oncology, 2012, 30, e13121-e13121.	1.6	0
112	Correlation of Ethnicity, Socioeconomic Status, and Co-Morbidity with Outcome After Allogeneic Hematopoietic Stem Cell Transplantation.. Blood, 2012, 120, 3102-3102.	1.4	0
113	Prognostic Value Of Disease Status At Time Of Allogeneic Transplant For Relapsed Non-Hodgkinâ€™s Lymphoma. Blood, 2013, 122, 3412-3412.	1.4	0
114	Germ-Line and Somatic Mutations in Familial Myeloproliferative Neoplasms (MPNs). a Pilot Study. Blood, 2014, 124, 3214-3214.	1.4	0
115	Quality of life EQ-5D results from the AETHERA trial: A phase III study of brentuximab vedotin consolidation following autologous stem cell transplant for HL.. Journal of Clinical Oncology, 2015, 33, 6568-6568.	1.6	0
116	Necroptosis of a Small Subset of Hematopoietic Progenitors Induces Autoimmune Bone Marrow Failure. Blood, 2015, 126, 4784-4784.	1.4	0
117	Infliximab and Low Dose Alemtuzumab in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease. Blood, 2016, 128, 5795-5795.	1.4	0
118	Autologous Transplantation As Consolidation for High Risk Aggressive T-Cell Non-Hodgkin's Lymphoma: A SWOG S9704 Intergroup Trial Subgroup Analysis. Blood, 2016, 128, 4651-4651.	1.4	0
119	Relationship between disease activity and circulating endothelial and endothelial progenitor cells in multiple myeloma.. Journal of Clinical Oncology, 2018, 36, e20004-e20004.	1.6	0
120	Impact of Graft Composition on Graft-Versus-Host Disease in Peripheral Blood HLA-Identical Sibling Transplants: Protective Role of CD8 Cell Dose. Blood, 2018, 132, 5719-5719.	1.4	0
121	Liposomal Daunorubicin/Cytarabine As a Bridge to Donor Lymphocyte Infusion or Allogeneic Stem Cell Transplantation for High-Risk Acute Myelogenous Leukemia. Blood, 2019, 134, 5726-5726.	1.4	0
122	Impact of immunoparesis on clinical outcomes following bone marrow transplantation.. Journal of Clinical Oncology, 2020, 38, e20505-e20505.	1.6	0
123	Hematopoietic Cell Transplantation of Higher CD34+ Cell Doses and Specific CD34+ Subsets Mobilized with Motixafortide and/or G-CSF Is Associated with Rapid Engraftment - a Post-Hoc Analysis of the Genesis Trial. Blood, 2021, 138, 2849-2849.	1.4	0
124	Mucositis: continuing progress for a continuing need. The Journal of Supportive Oncology, 2007, 5, 47-62.	2.3	0